Practice Signal

Ketamine & Esketamine for Treatment-Resistant Depression

Psychiatry 8 sources

Evidence at a Glance

Source	Grade / Verdict
Esketamine Monotherapy Shows Rapid Efficacy in Treatment-Resistant Depression Study · JAMA Psychiatry	Grade: Moderate Confirmatory
Oral Prolonged-Release Ketamine Misses Primary Endpoint, Avoids Dissociation Study · JAMA Network Open	Grade: Low Hypothesis-generating
Oral extended-release ketamine shows dose-related benefit in resistant depression Study · Nature Medicine	Grade: Low Hypothesis-generating
Fixed Low-Dose Oral Esketamine Fails in Treatment-Resistant Depression Study · Molecular Psychiatry	Grade: Low Inconclusive
Esketamine vs. Ketamine Safety in Depression Study · Frontiers in Pharmacology
Predictors of Ketamine's Effects in Depression Study · CNS Drugs
Oral Ketamine as a Practical, Low-Cost Option for Severe Depression Study · The Journal of Clinical Psychiatry	Grade: Very Low Hypothesis-generating
Ketamine Infusions in Bipolar Depression: Promising Yet Preliminary Study · Bipolar Disorders

🔒

Practice Recommendations: Subscribers Only

The bedside actions and open questions that turn this evidence into practice.

Practice Considerations: the bedside actions

Open Questions & evidence gaps

Want the full review?

Subscribe to PharmD Signal for the complete practice recommendations on every topic, plus every deep analysis we publish.

Become a Subscriber →

🎓

Synthesized and reviewed by a licensed pharmacist

Each Practice Signal is built from our published deep analyses and checked for clinical accuracy before it goes live.

Not medical advice. PharmD Signal provides educational synthesis of published pharmacy and medical literature for practicing pharmacists. It is not a treatment recommendation for any individual patient; clinical decisions remain the responsibility of the treating clinician exercising independent professional judgment.

Thanks for the feedback!

← Back to Evidence Rounds